228 related articles for article (PubMed ID: 29500696)
1. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
[TBL] [Abstract][Full Text] [Related]
2. Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
Al-Rashdi AA; Sabt BI; Al-Mujaini AS
BMC Ophthalmol; 2022 Dec; 22(1):470. PubMed ID: 36471269
[TBL] [Abstract][Full Text] [Related]
3. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
[TBL] [Abstract][Full Text] [Related]
4. Famous.
Kim MJ; Bhatti MT; Costello F
Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
[TBL] [Abstract][Full Text] [Related]
5. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
6. Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod.
Nørgaard TL; Andersen CU; Hilt C; Andersen CU
Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):492-497. PubMed ID: 31880065
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod-associated macular oedema.
Jasani KM; Sharaf N; Rog D; Aslam T
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
[No Abstract] [Full Text] [Related]
8. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
Schröder K; Finis D; Harmel J; Ringelstein M; Hartung HP; Geerling G; Aktas O; Guthoff R
Mult Scler Relat Disord; 2015 Sep; 4(5):406-408. PubMed ID: 26346788
[TBL] [Abstract][Full Text] [Related]
9. Does fingolimod in multiple sclerosis patients cause macular edema?
Turaka K; Bryan JS
J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
[TBL] [Abstract][Full Text] [Related]
10. Real-world incidence of fingolimod-associated macular oedema.
Goh LY; Kirthi V; Silber E; Harvey JP; Jackson TL
Mult Scler Relat Disord; 2020 Jul; 42():102125. PubMed ID: 32403070
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis.
Karaküçük Y; Gümüş H; Eker S
Cutan Ocul Toxicol; 2020 Sep; 39(3):281-286. PubMed ID: 32657164
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?
Pul R; Osmanovic A; Schmalstieg H; Pielen A; Pars K; Schwenkenbecher P; Sühs KW; Yildiz Ö; Frank B; Stangel M; Skripuletz T
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983657
[TBL] [Abstract][Full Text] [Related]
14. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
15. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Nolan R; Gelfand JM; Green AJ
Neurology; 2013 Jan; 80(2):139-44. PubMed ID: 23223539
[TBL] [Abstract][Full Text] [Related]
17. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod therapy and macular hemorrhage.
Bhatti MT; Freedman SM; Mahmoud TH
J Neuroophthalmol; 2013 Dec; 33(4):370-2. PubMed ID: 23845997
[TBL] [Abstract][Full Text] [Related]
19. [Early onset of fingolimod-associated macular edema].
Schelenz D; Kleiter I; Schöllhammer J; Rehrmann J; Elling M; Dick HB; Kakkassery V
Ophthalmologe; 2018 May; 115(5):424-428. PubMed ID: 28653209
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
